Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jordan J Feld

Showing results (151-160 of 395) with videos related to

Pageof 40
Sort By:
Scientific Reports|July 11, 2020
Optimized ex vivo stimulation identifies multi-functional HBV-specific T cells in a majority of chronic hepatitis B patientsConan G Chua, Aman Mehrotra, Tony Mazzulli, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|February 14, 2020
Evaluation of Sustained Virologic Response as a Relevant Surrogate Endpoint for Long-term Outcomes of Hepatitis C Virus InfectionLisette A P Krassenburg, Wayel R Zanjir, Firas Georgie, et al.
Annals of Surgical Oncology|December 14, 2022
Association of Viral Hepatitis Status and Post-hepatectomy Outcomes in the Era of Direct-Acting AntiviralsLuckshi Rajendran, Woo Jin Choi, Hala Muaddi, et al.
Hepatology (Baltimore, Md.)|March 13, 2024
Feasibility of hepatitis C elimination by screening and treatment alone in high-income countriesFeng Tian, Farinaz Forouzannia, Zeny Feng, et al.
Journal of Viral Hepatitis|January 9, 2025
Resistance-Associated Substitution Testing Trends and Impact on HCV Treatment Outcomes in Canada: A CanHepC-CANUHC AnalysisHimain Perera, Haris Imsirovic, Gisela Macphail, et al.
The Journal of Infectious Diseases|October 31, 2024
Hepatitis B Virus RNA as a Biomarker for Safe Antiviral Discontinuation: A Prospective Study of Nucleos(t)ide Analogue WithdrawalNorah A Terrault, Richard Sterling, Anna S Lok, et al.
Infectious Diseases and Therapy|February 17, 2022
Efficacy and Safety of 8- or 12 Weeks of Glecaprevir/Pibrentasvir in Patients with Evidence of Portal HypertensionRobert S Brown, Michelle A Collins, Simone I Strasser, et al.
Paediatrics & Child Health|September 8, 2025
Hepatitis C virus testing in infants, a move to early screening by HCV RNA at 2 months of ageMia J Biondi, Jennifer Flemming, Jennifer van Gennip, et al.
JHEP Reports : Innovation in Hepatology|December 1, 2025
Development of a CRE/CREB-driven HBx responsive HBV cell culture reporter system for antiviral drug evaluationMuhammad Atif Zahoor, Nahla FadlElMawla, Adrian Kuipery, et al.
Journal of Hepatology|August 27, 2013
Is there sufficient evidence to recommend antiviral therapy in hepatitis C?Adriaan J van der Meer, Heiner Wedemeyer, Jordan J Feld, et al.
Pageof 40

Showing results (151-160 of 395) with videos related to

Sort By:
Pageof 40
Scientific Reports|July 11, 2020
Optimized ex vivo stimulation identifies multi-functional HBV-specific T cells in a majority of chronic hepatitis B patientsConan G Chua, Aman Mehrotra, Tony Mazzulli, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|February 14, 2020
Evaluation of Sustained Virologic Response as a Relevant Surrogate Endpoint for Long-term Outcomes of Hepatitis C Virus InfectionLisette A P Krassenburg, Wayel R Zanjir, Firas Georgie, et al.
Annals of Surgical Oncology|December 14, 2022
Association of Viral Hepatitis Status and Post-hepatectomy Outcomes in the Era of Direct-Acting AntiviralsLuckshi Rajendran, Woo Jin Choi, Hala Muaddi, et al.
Hepatology (Baltimore, Md.)|March 13, 2024
Feasibility of hepatitis C elimination by screening and treatment alone in high-income countriesFeng Tian, Farinaz Forouzannia, Zeny Feng, et al.
Journal of Viral Hepatitis|January 9, 2025
Resistance-Associated Substitution Testing Trends and Impact on HCV Treatment Outcomes in Canada: A CanHepC-CANUHC AnalysisHimain Perera, Haris Imsirovic, Gisela Macphail, et al.
The Journal of Infectious Diseases|October 31, 2024
Hepatitis B Virus RNA as a Biomarker for Safe Antiviral Discontinuation: A Prospective Study of Nucleos(t)ide Analogue WithdrawalNorah A Terrault, Richard Sterling, Anna S Lok, et al.
Infectious Diseases and Therapy|February 17, 2022
Efficacy and Safety of 8- or 12 Weeks of Glecaprevir/Pibrentasvir in Patients with Evidence of Portal HypertensionRobert S Brown, Michelle A Collins, Simone I Strasser, et al.
Paediatrics & Child Health|September 8, 2025
Hepatitis C virus testing in infants, a move to early screening by HCV RNA at 2 months of ageMia J Biondi, Jennifer Flemming, Jennifer van Gennip, et al.
JHEP Reports : Innovation in Hepatology|December 1, 2025
Development of a CRE/CREB-driven HBx responsive HBV cell culture reporter system for antiviral drug evaluationMuhammad Atif Zahoor, Nahla FadlElMawla, Adrian Kuipery, et al.
Journal of Hepatology|August 27, 2013
Is there sufficient evidence to recommend antiviral therapy in hepatitis C?Adriaan J van der Meer, Heiner Wedemeyer, Jordan J Feld, et al.
Pageof 40